Konruns(SH:603590)2023-10-27 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥269,200,543.89, representing a year-over-year increase of 24.40%[5] - Net profit attributable to shareholders was ¥55,744,481.89, a significant increase of 157.69% compared to the same period last year[5] - The basic earnings per share for the quarter was ¥0.3562, reflecting a growth of 157.74% year-over-year[6] - Total operating revenue for the first three quarters of 2023 reached ¥720,036,091.76, an increase of 22.3% compared to ¥587,989,983.65 in the same period of 2022[24] - Operating profit for Q3 2023 was ¥188,525,591.16, up from ¥124,780,789.90 in Q3 2022, reflecting a growth of 50.9%[25] - Net profit attributable to shareholders for Q3 2023 was ¥148,633,516.03, compared to ¥103,670,197.97 in Q3 2022, marking an increase of 43.4%[26] - The company reported a total comprehensive income of ¥208,566,083.51 for Q3 2023, significantly higher than ¥56,944,245.33 in Q3 2022[26] - Basic and diluted earnings per share for Q3 2023 were both ¥0.9498, compared to ¥0.6625 in Q3 2022, an increase of 43.3%[26] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,776,504,386.47, marking a 10.27% increase from the end of the previous year[6] - Total assets as of Q3 2023 amounted to ¥3,776,504,386.47, up from ¥3,424,800,761.83 in the previous year, representing a growth of 10.3%[22] - Total liabilities increased to ¥363,472,430.68 in Q3 2023 from ¥234,675,395.76 in Q3 2022, indicating a rise of 55.0%[22] - The total equity attributable to shareholders was ¥3,133,509,656.51, which is a 7.10% increase compared to the previous year[6] Cash Flow - The company reported cash flow from operating activities of ¥146,391,282.13 for the year-to-date, an increase of 11.18%[5] - The net cash flow from operating activities for the first three quarters of 2023 was ¥146,391,282.13, up 11.9% from ¥131,673,194.89 in the first three quarters of 2022[29] - The cash inflow from sales of goods and services reached ¥714,904,768.62, an increase of 12.2% compared to ¥637,284,307.52 in the same period of 2022[29] - The cash inflow from investment activities significantly increased to ¥1,054,368,391.68 in the first three quarters of 2023, compared to ¥197,467,082.77 in the same period of 2022, marking a growth of 433.5%[30] - The cash inflow from financing activities totaled ¥179,188,810.54 in the first three quarters of 2023, with a net cash flow of ¥137,571,883.82, compared to a negative cash flow of -¥56,294,706.10 in the same period of 2022[30] - The total cash outflow for operating activities was ¥598,951,589.95 in the first three quarters of 2023, compared to ¥540,505,270.30 in the same period of 2022, reflecting an increase of 10.8%[29] Research and Development - The company has made progress in its R&D projects, including KC1036, which is currently in Phase II clinical trials with over 100 advanced solid tumor patients enrolled[16] - The clinical trial for Jin Cao Pian has successfully completed all subject enrollments for Phase III trials, which is expected to significantly improve patients' quality of life[17] - The new drug application for the canine injection of the Agkistrodon acutus blood coagulant has been accepted, marking a significant step in the pet pharmaceutical sector[17] - Research and development expenses for Q3 2023 were ¥67,219,009.80, compared to ¥54,706,235.57 in Q3 2022, reflecting a growth of 22.9%[25] Current Assets - As of September 30, 2023, the total current assets amounted to RMB 1,255,930,484.73, an increase from RMB 1,016,711,762.41 at the end of 2022, representing a growth of approximately 23.5%[20] - The cash and cash equivalents stood at RMB 344,803,088.25, slightly down from RMB 345,245,428.47 at the end of 2022[20] - The accounts receivable increased to RMB 295,007,979.11 from RMB 276,722,138.36, reflecting a growth of about 6.5%[20] - The inventory rose to RMB 44,484,860.21, compared to RMB 36,992,446.20 at the end of 2022, indicating an increase of approximately 20.0%[20] Stock and Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,517[12] - The company completed the initial registration of its 2023 restricted stock incentive plan on September 21, 2023[15] Non-Recurring Gains and Losses - The net profit after deducting non-recurring gains and losses for the quarter was ¥53,167,448.94, up 146.44% year-over-year[10] - Deferred income tax assets rose to ¥1,230,425.38 in Q3 2023 from ¥1,086,400.80 in Q3 2022, an increase of 13.2%[21] Investment Strategy - The total non-current assets were reported at RMB 2,052,000,000, reflecting a stable investment strategy amidst market fluctuations[20] - The company’s total non-current assets reached ¥2,520,573,901.74 in Q3 2023, up from ¥2,408,088,999.42 in Q3 2022, indicating a growth of 4.7%[21] Other Information - The company has not disclosed any new product developments or market expansion strategies in the provided financial reports[31]